Immunic to Participate in Industry and Investor Conferences in November

Core Insights - Immunic, Inc. is a biotechnology company focused on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases [1] - The lead development program, vidofludimus calcium (IMU-838), is in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026 [1] - The company is participating in several industry and investor conferences in November, including BIO-Europe and the Jefferies Global Healthcare Conference [3] Company Overview - Immunic, Inc. is listed on Nasdaq under the ticker IMUX and specializes in therapies for chronic inflammatory and autoimmune diseases [1] - Vidofludimus calcium acts as a first-in-class nuclear receptor-related 1 (Nurr1) activator and selectively inhibits dihydroorotate dehydrogenase (DHODH) [1] - Other development programs include IMU-856, targeting Sirtuin 6 (SIRT6) for gastrointestinal diseases, and IMU-381, currently in preclinical testing [1] Clinical Development - Vidofludimus calcium has shown therapeutic activity in phase 2 trials for relapsing-remitting and progressive multiple sclerosis [1] - IMU-856 aims to restore intestinal barrier function and could be applicable in various gastrointestinal diseases [1] - IMU-381 is being developed to address specific needs in gastrointestinal diseases and is currently in preclinical testing [1]